FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:911-923 March 2, 2006 Number 9 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Ropper, A. H. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an ₄ integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies.

Methods We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse during the 12-month period before randomization to receive continued interferon beta-1a in combination with 300 mg of natalizumab (589 patients) or placebo (582 patients) intravenously every 4 weeks for up to 116 weeks. The primary end points were the rate of clinical relapse at 1 year and the cumulative probability of disability progression sustained for 12 weeks, as measured by the Expanded Disability Status Scale, at 2 years.

Results Combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02). Kaplan–Meier estimates of the cumulative probability of progression at two years were 23 percent with combination therapy and 29 percent with interferon beta-1a alone. Combination therapy was associated with a lower annualized rate of relapse over a two-year period than was interferon beta-1a alone (0.34 vs. 0.75, P<0.001) and with fewer new or enlarging lesions on T₂-weighted magnetic resonance imaging (0.9 vs. 5.4, P<0.001). Adverse events associated with combination therapy were anxiety, pharyngitis, sinus congestion, and peripheral edema. Two cases of progressive multifocal leukoencephalopathy, one of which was fatal, were diagnosed in natalizumab-treated patients.

Conclusions Natalizumab added to interferon beta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing multiple sclerosis. Additional research is needed to elucidate the benefits and risks of this combination treatment. (ClinicalTrials.gov number, NCT00030966 [ClinicalTrials.gov] .)

Source Information

From the Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland (R.A.R.); the MS Center of Atlanta, Atlanta (W.H.S.); the Johns Hopkins Multiple Sclerosis Center, Baltimore (P.A.C.); Hôpital Neurologique, Lyon, France (C.C.); University of Pennsylvania School of Medicine, Philadelphia (S.L.G.); University Hospital Basel, Basel, Switzerland (E.-W.R.); Mt. Sinai School of Medicine, New York (F.D.L.); Baird Multiple Sclerosis Center, State University of New York at Buffalo, Buffalo (B.W.-G.); Consultants in Neurology Multiple Sclerosis Center, Northbrook, Ill. (D.R.W.); and Biogen Idec, Cambridge, Mass. (F.L., M.A.P., A.W.S.).

Address reprint requests to Dr. Rudick at the Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, or at rudickr{at}ccf.org.

Full Text of this Article

Related Letters:

Natalizumab for Relapsing Multiple Sclerosis
Tenser R. B., Jeffery D. R., Meyer M. A., Polman C. H., Rudick R. A., Major E. O., Yousry T. A., Clifford D. B., Ropper A. H.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2387-2389, Jun 1, 2006. Correspondence

This article has been cited by other articles:

• Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L., the TRANSFORMS Study Group, (2010). Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. NEJM 362: 402-415 [Abstract] [Full Text]  
• Bielekova, B., Becker, B. L. (2010). Monoclonal antibodies in MS: Mechanisms of action. Neurology 74: S31-S40 [Abstract] [Full Text]  
• Remington, G. M., Treadaway, K., Frohman, T., Salter, A., Stuve, O., Racke, M. K., Hawker, K., Agosta, F., Sormani, M. P., Filippi, M., Frohman, E. M. (2010). A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing--remitting multiple sclerosis (TIME MS). Therapeutic Advances in Neurological Disorders 3: 3-13 [Abstract]  
• Graham, K. L., Zabel, B. A., Loghavi, S., Zuniga, L. A., Ho, P. P., Sobel, R. A., Butcher, E. C. (2009). Chemokine-Like Receptor-1 Expression by Central Nervous System-Infiltrating Leukocytes and Involvement in a Model of Autoimmune Demyelinating Disease. J. Immunol. 183: 6717-6723 [Abstract] [Full Text]  
• Coyle, P. K, Jeffery, D. R (2009). Clinical efficacy and benefit of natalizumab. Mult Scler 15: S7-S15 [Abstract]  
• Tornatore, C., Clifford, D. B (2009). Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use. Mult Scler 15: S16-S25 [Abstract]  
• Coyle, P. K, Foley, J. F, Fox, E. J, Jeffery, D. R, Munschauer, F. E III, Tornatore, C. (2009). Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Mult Scler 15: S26-S36 [Abstract]  
• Stuve, O., Wiendl, H. (2009). Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected?. Neurology 73: 1346-1347 [Full Text]  
• Nishimura, S. L. (2009). Integrin-Mediated Transforming Growth Factor-{beta} Activation, a Potential Therapeutic Target in Fibrogenic Disorders. Am. J. Pathol. 175: 1362-1370 [Abstract] [Full Text]  
• Klawiter, E. C., Cross, A. H., Naismith, R. T. (2009). The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?. Neurology 73: 984-990 [Abstract] [Full Text]  
• Wenning, W., Haghikia, A., Laubenberger, J., Clifford, D. B., Behrens, P. F., Chan, A., Gold, R. (2009). Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. NEJM 361: 1075-1080 [Abstract] [Full Text]  
• Rudick, R., Polman, C., Cohen, J., Walton, M., Miller, A., Confavreux, C, Lublin, F., Hutchinson, M, O'Connor, P., Schwid, S., Balcer, L., Lynn, F, Panzara, M., Sandrock, A. (2009). Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 15: 984-997 [Abstract]  
• Helliwell, C. L., Coles, A. J. (2009). Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Therapeutic Advances in Neurological Disorders 2: 195-203  
• Rudick, R. A., Pace, A., Rani, M.R.S., Hyde, R., Panzara, M., Appachi, S., Shrock, J., Maurer, S. L., Calabresi, P. A., Confavreux, C., Galetta, S. L., Lublin, F. D., Radue, E. -W., Ransohoff, R. M. (2009). Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72: 1989-1993 [Abstract] [Full Text]  
• Coisne, C., Mao, W., Engelhardt, B. (2009). Cutting Edge: Natalizumab Blocks Adhesion but Not Initial Contact of Human T Cells to the Blood-Brain Barrier In Vivo in an Animal Model of Multiple Sclerosis. J. Immunol. 182: 5909-5913 [Abstract] [Full Text]  
• Killestein, J, Jasperse, B, Liedorp, M, Seewann, A, Polman, C. (2009). Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies. Mult Scler 15: 525-526  
• Goodman, A. D., Rossman, H., Bar-Or, A., Miller, A., Miller, D. H., Schmierer, K., Lublin, F., Khan, O., Bormann, N. M., Yang, M., Panzara, M. A., Sandrock, A. W., For the GLANCE Investigators, (2009). GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 72: 806-812 [Abstract] [Full Text]  
• Yaldizli, O., Putzki, N. (2009). Review: Natalizumab in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders 2: 115-128 [Abstract]  
• Cohen, J. A., Imrey, P. B., Calabresi, P. A., Edwards, K. R., Eickenhorst, T., Felton, W. L. III, Fisher, E., Fox, R. J., Goodman, A. D., Hara-Cleaver, C., Hutton, G. J., Mandell, B. F., Scott, T. F., Zhang, H., Apperson-Hansen, C., Beck, G. J., Houghtaling, P. L., Karafa, M. T., Stadtler, M., For the ACT Investigators, (2009). Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72: 535-541 [Abstract] [Full Text]  
• Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J-C, Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., Duda, P. W., Panzara, M. A., Ransohoff, R. M., Fox, R. J. (2009). Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402-409 [Abstract] [Full Text]  
• Stuve, O., Cravens, P. D., Frohman, E. M., Phillips, J. T., Remington, G. M., von Geldern, G., Cepok, S., Singh, M. P., Cohen Tervaert, J. W., De Baets, M., MacManus, D., Miller, D. H., Radu, E. W., Cameron, E. M., Monson, N. L., Zhang, S., Kim, R., Hemmer, B., Racke, M. K. (2009). Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72: 396-401 [Abstract] [Full Text]  
• Coyle, P, Arnason, B, Hurwitz, B, Lublin, F (2009). Optimizing Outcomes in Multiple Sclerosis - A Consensus Initiative. Mult Scler 15: S5-S35 [Abstract]  
• Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology 71: S8-S13 [Abstract] [Full Text]  
• Huppke, P., Stark, W., Zurcher, C., Huppke, B., Bruck, W., Gartner, J. (2008). Natalizumab Use in Pediatric Multiple Sclerosis. Arch Neurol 65: 1655-1658 [Abstract] [Full Text]  
• Martin, M. d. P., Cravens, P. D., Winger, R., Frohman, E. M., Racke, M. K., Eagar, T. N., Zamvil, S. S., Weber, M. S., Hemmer, B., Karandikar, N. J., Kleinschmidt-DeMasters, B. K., Stuve, O. (2008). Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Arch Neurol 65: 1596-1603 [Abstract] [Full Text]  
• Wekerle, H (2008). Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 67: iii56-iii60 [Abstract] [Full Text]  
• Hermann, D. M. (2008). Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier. Therapeutic Advances in Neurological Disorders 1: 167-179 [Abstract]  
• Rieckmann, P., Traboulsee, A., Devonshire, V., Oger, J. (2008). Review: Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 181-192 [Abstract]  
• Hauser, S. L. (2008). Multiple Lessons for Multiple Sclerosis. NEJM 359: 1838-1841 [Full Text]  
• Goodin, D. S., Cohen, B. A., O'Connor, P., Kappos, L., Stevens, J. C. (2008). Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71: 766-773 [Abstract] [Full Text]  
• (2008). {blacktriangledown}Natalizumab for multiple sclerosis?. DTB 46: 69-72 [Abstract] [Full Text]  
• Centonze, D, Furlan, R, Gasperini, C, Salvetti, M, Battistini, L (2008). Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Mult Scler 14: 1137-1138 [Abstract]  
• Marrie, R. A. (2008). You get what you measure: Evaluating endpoints in MS clinical trials. Neurology 71: 620-621 [Full Text]  
• Linker, R. A., Kieseier, B. C. (2008). Review: Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 33-42 [Abstract]  
• Vuaillat, C., Androdias, G., Davoust, N., Nataf, S. (2008). About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors. Blood 112: 208-209 [Full Text]  
• Berger, J. (2008). Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Mult Scler 14: 708-710 [Abstract]  
• Vollmer, T, Panitch, H, Bar-Or, A, Dunn, J, Freedman, M., Gazda, S., Campagnolo, D, Deutsch, F, Arnold, D. (2008). Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14: 663-670 [Abstract]  
• Cohen, J., Calabresi, P., Chakraborty, S., Edwards, K., Eickenhorst, T., Felton, W. III, Fisher, E., Fox, R., Goodman, A., Hara-Cleaver, C., Hutton, G., Imrey, P., Ivancic, D., Mandell, B., Perryman, J., Scott, T., Skaramagas, T., Zhang, H. for the AC (2008). Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler 14: 370-382 [Abstract]  
• Polman, C. H., Reingold, S. C., Barkhof, F., Calabresi, P. A., Clanet, M., Cohen, J. A., Cutter, G. R., Freedman, M. S., Kappos, L., Lublin, F. D., McFarland, H. F., Metz, L. M., Miller, A. E., Montalban, X., O'Connor, P. W., Panitch, H., Richert, J. R., Petkau, J., Schwid, S. R., Sormani, M. P., Thompson, A. J., Weinshenker, B. G., Wolinsky, J. S. (2008). Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology 70: 1134-1140 [Abstract] [Full Text]  
• Vellinga, M. M., Castelijns, J. A., Barkhof, F., Uitdehaag, B.M.J., Polman, C. H. (2008). POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS. Neurology 70: 1150-1151 [Full Text]  
• Ilanjian, H., Shane, R. (2008). Washout period for immune-modifying drugs before natalizumab therapy. Am J Health Syst Pharm 65: 18-19 [Full Text]  
• Cabrelle, A., Dell'Aica, I., Melchiori, L., Carraro, S., Brunetta, E., Niero, R., Scquizzato, E., D'Intino, G., Calza, L., Garbisa, S., Agostini, C. (2008). Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. J. Leukoc. Biol. 83: 212-219 [Abstract] [Full Text]  
• Doring, A., Wild, M., Vestweber, D., Deutsch, U., Engelhardt, B. (2007). E- and P-Selectin Are Not Required for the Development of Experimental Autoimmune Encephalomyelitis in C57BL/6 and SJL Mice. J. Immunol. 179: 8470-8479 [Abstract] [Full Text]  
• Santomasso, B. D., Roberts, W. K., Thomas, A., Williams, T., Blachere, N. E., Dudley, M. E., Houghton, A. N., Posner, J. B., Darnell, R. B. (2007). A T cell receptor associated with naturally occurring human tumor immunity. Proc. Natl. Acad. Sci. USA 104: 19073-19078 [Abstract] [Full Text]  
• Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Lublin, F. D., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., For the AFFIRM and SENTINEL Investigators, (2007). The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 69: 1391-1403 [Abstract] [Full Text]  
• Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P., Rostami, A. (2007). SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis. IOVS 48: 3602-3609 [Abstract] [Full Text]  
• Ransohoff, R. M. (2007). Natalizumab for Multiple Sclerosis. NEJM 356: 2622-2629 [Full Text]  
• Dorsey, E. R., Thompson, J. P., Noyes, K., Dick, A. W., Holloway, R. G., Schwid, S. R. (2007). Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 68: 1524-1528 [Abstract] [Full Text]  
• Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., for the AFFIRM and SENTINEL Investigators, (2007). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304 [Abstract] [Full Text]  
• Pohl, D., Waubant, E., Banwell, B., Chabas, D., Chitnis, T., Weinstock-Guttman, B., Tenembaum, S., for the International Pediatric MS Study Group, (2007). Treatment of pediatric multiple sclerosis and variants. Neurology 68: S54-S65 [Abstract] [Full Text]  
• Sweet, B. V. (2007). Natalizumab update. Am J Health Syst Pharm 64: 705-716 [Abstract] [Full Text]  
• Choudry, B. A., Chan, J. W. (2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20: 167-180 [Abstract]  
• Khalili, K., White, M. K., Lublin, F., Ferrante, P., Berger, J. R. (2007). Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68: 985-990 [Abstract] [Full Text]  
• Stuve, O., Marra, C. M., Cravens, P. D., Singh, M. P., Hu, W., Lovett-Racke, A., Monson, N. L., Phillips, J. T., Tervaert, J. W. C., Nash, R. A., Hartung, H.-P., Kieseier, B. C., Racke, M. M., Frohman, E. M., Hemmer, B. (2007). Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions. Arch Neurol 64: 169-176 [Abstract] [Full Text]  
• Johnston, S. L (2007). Biologic therapies: what and when?. J. Clin. Pathol. 60: 8-17 [Abstract] [Full Text]  
• Phillips, J. T., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Polman, C. H., Lublin, F. D., Giovannoni, G., Wajgt, A., Lynn, F., Panzara, M. A., Sandrock, A. W., for the AFFIRM Investigators, (2006). Infusion-related hypersensitivity reactions during natalizumab treatment.. Neurology 67: 1717-1718 [Full Text]  
• Stuve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., Cook, L., Grand'Maison, F., Hemmer, B., Monson, N. L., Racke, M. K. (2006). Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.. Arch Neurol 63: 1383-1387 [Abstract] [Full Text]  
• Noseworthy, J. H. (2006). How much can we learn from long-term extension trials in multiple sclerosis?. Neurology 67: 930-931 [Full Text]  
• (2006). Other articles noted. Evid. Based Med. 11: 127-128 [Full Text]  
• Gold, R., Hohlfeld, R. (2006). Multiple sclerosis therapy: new agents carry new risks. PN 6: 248-251 [Full Text]  
• Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952 [Abstract] [Full Text]  
• Tenser, R. B., Jeffery, D. R., Meyer, M. A., Polman, C. H., Rudick, R. A., Major, E. O., Yousry, T. A., Clifford, D. B., Ropper, A. H. (2006). Natalizumab for relapsing multiple sclerosis.. NEJM 354: 2387-2389 [Full Text]  
• (2006). Two-Year Benefit from Natalizumab for MS. JWatch Neurology 2006: 1-1 [Full Text]  
• (2006). Promise and Peril of Natalizumab for MS. JWatch General 2006: 3-3 [Full Text]  
• Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., Sandrock, A. W., the AFFIRM Investigators, (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.. NEJM 354: 899-910 [Abstract] [Full Text]  
• Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E.-W., Jager, H. R., Clifford, D. B. (2006). Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.. NEJM 354: 924-933 [Abstract] [Full Text]  
• Ropper, A. H. (2006). Selective treatment of multiple sclerosis.. NEJM 354: 965-967 [Full Text]